16 Publications
2015
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity.
Li, NLee, KXi, YZhu, BGary, B DRamírez-Alcántara, VGurpinar, ECanzoneri, J CFajardo, ASigler, SPiazza, J TChen, XAndrews, JThomas, MLu, WLi, YLaan, D JMoyer, M PRusso, SEberhardt, B TYet, LKeeton, A BGrizzle, W E and Piazza, G A
Oncogene, vol. 34, (no. 12), pp. 1499-1509, March 19, 2015. | Journal Article
 
Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10.
Li, NanChen, XiZhu, BingRamírez-Alcántara, VerónicaCanzoneri, Joshua CLee, KevinSigler, SaraGary, BernardLi, YongheZhang, WeiMoyer, Mary PSalter, E AlanWierzbicki, AndrzejKeeton, Adam B and Piazza, Gary A
Oncotarget, vol. 6, (no. 29), pp. 27403-27415, September 29, 2015. | Journal Article
2014
NSAIDs inhibit tumorigenesis, but how?
Gurpinar, EvrimGrizzle, William E and Piazza, Gary A
Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 20, (no. 5), pp. 1104-1113, March 1, 2014. | Journal Article
 
The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment.
Fajardo, Alexandra MPiazza, Gary A and Tinsley, Heather N
Cancers, vol. 6, (no. 1), pp. 436-458, February 26, 2014. | Journal Article
2013
6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.
Hamed, Mostafa MAbou El Ella, Dalal AKeeton, Adam BPiazza, Gary AAbadi, Ashraf HHartmann, Rolf W and Engel, Matthias
ChemMedChem, vol. 8, (no. 9), pp. 1495-1504, September 2013. | Journal Article
 
MicroRNA and cancer chemoprevention.
Yi, BinPiazza, Gary ASu, Xiulan and Xi, Yaguang
Cancer prevention research (Philadelphia, Pa.), vol. 6, (no. 5), pp. 401-409, May 2013. | Journal Article
 
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.
Li, NanXi, YaguangTinsley, Heather NGurpinar, EvrimGary, Bernard DZhu, BingLi, YongheChen, XiKeeton, Adam BAbadi, Ashraf HMoyer, Mary PGrizzle, William EChang, Wen-ChiClapper, Margie L and Piazza, Gary A
Molecular cancer therapeutics, vol. 12, (no. 9), pp. 1848-59, 2013/Sep. | Journal Article
2012
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.
Whitt, Jason DLi, NanTinsley, Heather NChen, XiZhang, WeiLi, YongheGary, Bernard DKeeton, Adam BXi, YaguangAbadi, Ashraf HGrizzle, William E and Piazza, Gary A
Cancer prevention research (Philadelphia, Pa.), vol. 5, (no. 6), pp. 822-833, June 2012. | Journal Article
 
Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases.
Tinsley, Heather N and Piazza, Gary A
Current colorectal cancer reports, vol. 8, (no. 4), pp. 325-330, December 2012. | Journal Article
 
Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs.
Li, XGao, LCui, QGary, B DDyess, D LTaylor, WShevde, L ASamant, R SDean-Colomb, WPiazza, G A and Xi, Y
Oncogene, vol. 31, (no. 48), pp. 4979-4986, November 29, 2012. | Journal Article
2011
Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells.
Tinsley, Heather NGary, Bernard DKeeton, Adam BLu, WenyanLi, Yonghe and Piazza, Gary A
Cancer prevention research (Philadelphia, Pa.), vol. 4, (no. 8), pp. 1275-1284, August 2011. | Journal Article
2010
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Tinsley, Heather NGary, Bernard DThaiparambil, JoseLi, NanLu, WenyanLi, YongheMaxuitenko, Yulia YKeeton, Adam B and Piazza, Gary A
Cancer prevention research (Philadelphia, Pa.), vol. 3, (no. 10), pp. 1303-1313, October 2010. | Journal Article
2009
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.
Piazza, Gary AKeeton, Adam BTinsley, Heather NGary, Bernard DWhitt, Jason DMathew, BiniThaiparambil, JoseCoward, LoriGorman, GregoryLi, YongheSani, BrahmaHobrath, Judith VMaxuitenko, Yulia Y and Reynolds, Robert C
Cancer prevention research (Philadelphia, Pa.), vol. 2, (no. 6), pp. 572-580, June 2009. | Journal Article
 
Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation.
Lu, WenyanTinsley, Heather NKeeton, AdamQu, ZhicanPiazza, Gary A and Li, Yonghe
European journal of pharmacology, vol. 602, (no. 1), pp. 8-14, January 5, 2009. | Journal Article
2004
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.
Basler, Joseph W and Piazza, Gary A
The Journal of urology. , vol. 171, (no. 2 Pt 2), pp. S59-62; discussion S62-3, 2004/Feb. | Journal Article
1999
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis.
Stoner, Gary DBudd, G. TGanapathi, RamDeYoung, BDeyoung, Barry RKresty, Laura ANitert, MFryer, BChurch, J MProvencher, KPamukcu, RPiazza, GHawk, EKelloff, GElson, P and van Stolk, R U
Advances in experimental medicine and biology, vol. 470, pp. 45-53, 1999. | Journal Article